- Home
- CELC vs ALMS Comparison
CELC vs ALMS Comparison
Compare CELC & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- ALMS
- Stock Information
- Founded
- CELC 2011
- ALMS 2021
- Country
- CELC United States
- ALMS United States
- Employees
- CELC N/A
- ALMS N/A
- Industry
- CELC Medical Specialities
- ALMS
- Sector
- CELC Health Care
- ALMS
- Exchange
- CELC Nasdaq
- ALMS NYSE
- Market Cap
- CELC 440.0M
- ALMS 402.6M
- IPO Year
- CELC 2017
- ALMS 2024
- Fundamental
- Price
- CELC $13.04
- ALMS $3.28
- Analyst Decision
- CELC Strong Buy
- ALMS Strong Buy
- Analyst Count
- CELC 6
- ALMS 7
- Target Price
- CELC $30.67
- ALMS $24.50
- AVG Volume (30 Days)
- CELC 196.9K
- ALMS 855.0K
- Earning Date
- CELC 08-13-2025
- ALMS 08-12-2025
- Dividend Yield
- CELC N/A
- ALMS N/A
- EPS Growth
- CELC N/A
- ALMS N/A
- EPS
- CELC N/A
- ALMS N/A
- Revenue
- CELC N/A
- ALMS $17,389,000.00
- Revenue This Year
- CELC N/A
- ALMS N/A
- Revenue Next Year
- CELC N/A
- ALMS N/A
- P/E Ratio
- CELC N/A
- ALMS N/A
- Revenue Growth
- CELC N/A
- ALMS N/A
- 52 Week Low
- CELC $7.58
- ALMS $2.76
- 52 Week High
- CELC $19.77
- ALMS $13.50
- Technical
- Relative Strength Index (RSI)
- CELC 60.10
- ALMS N/A
- Support Level
- CELC $12.48
- ALMS N/A
- Resistance Level
- CELC $13.60
- ALMS N/A
- Average True Range (ATR)
- CELC 0.74
- ALMS 0.00
- MACD
- CELC 0.04
- ALMS 0.00
- Stochastic Oscillator
- CELC 75.91
- ALMS 0.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.